Clinical trial
A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line…
NCT00251472 · Veeda Oncology, Other · Completed
Key facts
| NCT number | NCT00251472 |
|---|---|
| Title | A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer |
| Official title | A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer |
| Lead sponsor | Veeda Oncology, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Paclitaxel Albumin Nanoparticle for Injectable Suspension |
| Enrollment | 72 |
| Start date | Mar 1, 2005 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Nov 10, 2005 |
| Last update posted | May 11, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: